アンゼリカ・シネンシス由来の複雑な多環式二量体フタリド類とその腎線維症を軽減する可能性
Hang Lv1, Bixuan Cao1, Yu Mu1
1Key Laboratory of Bioresource Research and Development of Liaoning Province, College of Life and Health Sciences, Northeastern University, Shenyang 110819, People's Republic of China.
Abstract:
Chronic kidney disease (CKD), characterized by fibrosis, is primarily treated clinically by regulating excessive renin-angiotensin-aldosterone system (RAAS). Our previous research showed that dimeric phthalides from Angelica sinensis had the potential to alleviate CKD by suppressing renin expression and RAAS activation. To advance the search for anti-fibrotic and nephroprotective natural phthalides, a systematic investigation of phthalide polymers of A. sinensis was conducted. In this work, twenty-five dimeric phthalides, including seven new dimers, angesinenolides G-M (1, 13, 17, 18, 22-24), and eighteen known congeners were isolated from A. sinensis. The structures of new compounds were elucidated by spectroscopic and crystallographic data analyses. The anti-fibrosis activities of these phthalides were evaluated in TGF-β1-stimulated HK-2 cells. The results revealed that phthalide dimers 5 (tokinolide A, TA) and 13 significantly reduced the level of renin gene and down-regulated the fibrosis-related protein markers such as fibronectin (Fn), collagen I (Col I), E-cadherin and α-SMA. Mechanistically, treatment with phthalide dimers reduced the levels of renin and Ang II in the RAAS pathway and inhibited the activation of TGF-β1/Smad signaling pathway in TGF-β1-stimulated cells. In the 5/6 nephrectomy (Nx) model, the anti-renal fibrotic efficacy of TA was further substantiated, with in vivo mechanisms consistent with the cellular findings. Overall, these findings expanded the natural phthalide dimers of A. sinensis and supported TA as an attractive lead compound for renal fibrosis and renin-targeted CKD therapy.
さらに関連する動画
関連する概念動画
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...


